Dear Colleagues,

A high incidence of antimicrobial resistance in pathogenic microorganisms causing a major threat to human survival has been emerging over the last few decades. The major reason for this resistance was found to be the formation of biofilms by these pathogenic microbes, although they display multiple resistance mechanisms. Biofilms are a self-assemblage of the bacterial population encased by a self-produced extracellular polymeric substances such as exopolysaccharides, eDNA, and extracellular proteins. These pathogenic microorganisms also produce several toxins and virulence factors that contribute towards pathogenesis. In response to combating the infections caused by these microbes, several recent and past studies have developed alternative strategies. These strategies include the application of biologically derived or chemically synthesized active compounds as antibiofilm and antivirulence agents. Furthermore, these compounds have also been employed in different formulations, such as through conjugation, immobilization, or their encapsulation in polymeric biocompatible materials. Considering the continuous emergence of new antibiotic-resistant microbial strains, there is a high demand to screen antibiofilm and antivirulence drugs. The antibiofilm drugs derived from marine organisms are considered as potential drugs due to their negligible cytotoxicity and high biocompatibility properties. In addition, marine-derived polymeric substances, including fucoidan, carrageenan, alginate, and chitosan, have also been exploited as a carrier for the pre-existing antibiofilm or antivirulence drugs whose instability and hydrophobicity have precluded their successful delivery.

As Guest Editors for this Special Issue, we invite all researchers to submit their findings related to antibiofilm and antivirulence drugs derived from marine organisms for the upcoming Special Issue “Marine Natural Products with Antibiofilm and Antivirulence Activity”.

Prof. Dr. Young-mog Kim
Dr. Fazlurrahman Khan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antibiofilm
• antivirulence
• bioactive molecules
• conjugation
• drug delivery
• drug discovery
• encapsulation
• marine products
• marine organisms
• nanocomposites
• pathogens
• secondary metabolites

• Marine Antibiotics 2020 in Marine Drugs (6 articles)